NO874851L - Natriumfluoridtablett med langsom frigjoering, fremstilling derav, og fremgangsmaate ved behandling av osteoporose. - Google Patents

Natriumfluoridtablett med langsom frigjoering, fremstilling derav, og fremgangsmaate ved behandling av osteoporose.

Info

Publication number: NO874851L
Authority: NO; Norway
Prior art keywords: sodium fluoride; fluoride; slow; preparation; release
Prior art date: 1986-03-21

Application number

NO874851A

Other languages

English (en)

Norwegian (no)

Other versions

NO874851D0 (no

Inventor

Neill B Walsdorf

Charles Y C Pak

Original Assignee

Univ Texas

Mission Pharma Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-03-21

Filing date

1987-11-20

Publication date

1988-01-20

1986-03-21 Priority claimed from US06/842,304 external-priority patent/US4726952A/en

1987-11-20 Application filed by Univ Texas, Mission Pharma Co filed Critical Univ Texas

1987-11-20 Publication of NO874851D0 publication Critical patent/NO874851D0/no

1988-01-20 Publication of NO874851L publication Critical patent/NO874851L/no

Links

PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 title claims abstract description 144
235000013024 sodium fluoride Nutrition 0.000 title claims abstract description 72
239000011775 sodium fluoride Substances 0.000 title claims abstract description 72
238000002360 preparation method Methods 0.000 title claims abstract description 33
208000001132 Osteoporosis Diseases 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title claims description 12
210000002966 serum Anatomy 0.000 claims abstract description 34
210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
210000000988 bone and bone Anatomy 0.000 claims description 29
230000001225 therapeutic effect Effects 0.000 claims description 11
210000004051 gastric juice Anatomy 0.000 claims description 3
230000000968 intestinal effect Effects 0.000 claims description 3
238000004090 dissolution Methods 0.000 claims description 2
230000028327 secretion Effects 0.000 claims description 2
210000000813 small intestine Anatomy 0.000 claims description 2
208000029725 Metabolic bone disease Diseases 0.000 claims 1
206010049088 Osteopenia Diseases 0.000 claims 1
235000013869 carnauba wax Nutrition 0.000 claims 1
239000004203 carnauba wax Substances 0.000 claims 1
150000003431 steroids Chemical class 0.000 claims 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 abstract description 49
238000011282 treatment Methods 0.000 abstract description 19
230000000694 effects Effects 0.000 abstract description 13
210000002784 stomach Anatomy 0.000 abstract description 10
208000025747 Rheumatic disease Diseases 0.000 abstract description 9
230000000552 rheumatic effect Effects 0.000 abstract description 9
231100000331 toxic Toxicity 0.000 abstract description 7
230000002588 toxic effect Effects 0.000 abstract description 7
238000012423 maintenance Methods 0.000 abstract description 3
230000011164 ossification Effects 0.000 abstract description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 12
206010017076 Fracture Diseases 0.000 description 8
230000007774 longterm Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 6
230000002496 gastric effect Effects 0.000 description 6
208000010392 Bone Fractures Diseases 0.000 description 5
102000004067 Osteocalcin Human genes 0.000 description 5
108090000573 Osteocalcin Proteins 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
230000001009 osteoporotic effect Effects 0.000 description 5
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
206010067484 Adverse reaction Diseases 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
230000006838 adverse reaction Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
238000002666 fluoride therapy Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000008693 nausea Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
206010016228 Fasciitis Diseases 0.000 description 2
206010016818 Fluorosis Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
229940069978 calcium supplement Drugs 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
208000004042 dental fluorosis Diseases 0.000 description 2
238000013461 design Methods 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
231100000816 toxic dose Toxicity 0.000 description 2
206010065687 Bone loss Diseases 0.000 description 1
241000252206 Cypriniformes Species 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010053155 Epigastric discomfort Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000906034 Orthops Species 0.000 description 1
208000001164 Osteoporotic Fractures Diseases 0.000 description 1
206010034156 Pathological fracture Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000009704 beneficial physiological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000037182 bone density Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003518 caustics Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910001610 cryolite Inorganic materials 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000005530 etching Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
208000035861 hematochezia Diseases 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
208000025636 skeletal fluorosis Diseases 0.000 description 1
241000894007 species Species 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO874851A 1986-03-21 1987-11-20 Natriumfluoridtablett med langsom frigjoering, fremstilling derav, og fremgangsmaate ved behandling av osteoporose. NO874851L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/842,304 US4726952A (en)	1983-08-11	1986-03-21	Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
PCT/US1987/000624 WO1987005463A2 (en)	1986-03-21	1987-03-19	Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis

Publications (2)

Publication Number	Publication Date
NO874851D0 NO874851D0 (no)	1987-11-20
NO874851L true NO874851L (no)	1988-01-20

Family

ID=26775642

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO874851A NO874851L (no)	1986-03-21	1987-11-20	Natriumfluoridtablett med langsom frigjoering, fremstilling derav, og fremgangsmaate ved behandling av osteoporose.

Country Status (2)

Country	Link
DK (1)	DK610187A (da)
NO (1)	NO874851L (da)

1987
- 1987-11-20 DK DK610187A patent/DK610187A/da unknown
- 1987-11-20 NO NO874851A patent/NO874851L/no unknown

Also Published As

Publication number	Publication date
DK610187D0 (da)	1987-11-20
NO874851D0 (no)	1987-11-20
DK610187A (da)	1987-11-20

Publication	Publication Date	Title
Agnusdei et al.	1997	Efficacy of ipriflavone in established osteoporosis and long-term safety
KR100372966B1 (ko)	2003-05-12	경구투여용액체알렌드로네이트제형
Boutsen et al.	1997	Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial
US20020072541A1 (en)	2002-06-13	Use of creatine and/or creatine derivatives for treating typical disorders in women
EA004573B1 (ru)	2004-06-24	Способы лечения женщин в постклимактерическом состоянии с применением ультранизких доз эстрогена
US4726952A (en)	1988-02-23	Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
EP0809502A1 (en)	1997-12-03	Method of lessening the risk of non-vertebral bone fractures
Breslau	1994	Calcium, estrogen, and progestin in the treatment of osteoporosis
JPH01151515A (ja)	1989-06-14	骨粗鬆症および関連障害の治療法
US6441041B1 (en)	2002-08-27	(-)-hydroxycitric acid for the prevention of osteoporosis
EP0337938A2 (en)	1989-10-18	19-Norprogesterone derivatives in the treatment of osteoporosis
JPS6393710A (ja)	1988-04-25	フッ素イオンとカルシウムの持続放出組成物
CA1340743C (en)	1999-09-14	Compositions for the treatment of ostoporosis in humans
AU713824B2 (en)	1999-12-09	Prevention of tooth loss by the administration of alendronate or its salts
NO874851L (no)	1988-01-20	Natriumfluoridtablett med langsom frigjoering, fremstilling derav, og fremgangsmaate ved behandling av osteoporose.
Ringe et al.	2002	Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study
AU709196B2 (en)	1999-08-26	Use of alendronate for the prevention of osteoporosis
US20020169148A1 (en)	2002-11-14	Use of alendronate for the prevention of osteoporosis
Pak et al.	1990	Effect of intermittent therapy with a slow‐release fluoride preparation
JP2021518438A (ja)	2021-08-02	男性の避妊のための非ホルモン性組成物および方法
AU2013349776A1 (en)	2015-05-28	Use and application regimen of a pharmaceutical composition containing levonorgestrel and a COX inhibitor for on-demand contraception
HU230467B1 (hu)	2016-07-28	Új fogamzásgátló gyógyszer és eljárás előállítására
WO1996004917A1 (en)	1996-02-22	Remedy for myotonic dystrophy
Devogelaer	1998	A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis
HU211084B (en)	1995-10-30	Process for producing oral pharmaceutical composition of bone strengthening activity